Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/12088
Title: Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity.
Authors: Ung, Nelson;Putoczki, Tracy L;Stylli, Stanley S;Ng, Irvin;Mariadason, John M;Chan, Timothy A;Zhu, Hong-Jian;Luwor, Rodney B
Affiliation: Department of Surgery; The University of Melbourne; The Royal Melbourne Hospital; Parkville, VIC Australia.
Department of Surgery; The University of Melbourne; The Royal Melbourne Hospital; Parkville, VIC Australia; Inflammation Division; Walter and Eliza Hall Institute of Medical Research; Parkville, VIC Australia; Department of Medical Biology; The University of Melbourne; Parkville, VIC Australia.
Department of Surgery; The University of Melbourne; The Royal Melbourne Hospital; Parkville, VIC Australia; Department of Neurosurgery; The Royal Melbourne Hospital; Parkville, VIC Australia.
Ludwig Institute for Cancer Research; Austin Health; Heidelberg, VIC Australia.
Human Oncology and Pathogenesis Program and Department of Radiation Oncology; Memorial Sloan-Kettering Cancer Center; New York, NY USA.
Department of Surgery; The University of Melbourne; The Royal Melbourne Hospital; Parkville, VIC Australia; Department of Medicine; The University of Melbourne; The Royal Melbourne Hospital; Parkville, VIC Australia.
Issue Date: 20-Feb-2014
Citation: Cancer Biology & Therapy 2014; 15(5): 623-32
Abstract: Several agents targeting the epidermal growth factor receptor (EGFR) have been FDA-approved to treat cancer patients with varying tumor types including metastatic colorectal cancer. Many patients treated with anti-EGFR therapy however do not respond and those that do initially respond often acquire resistance. Here we show a clear correlation between the efficacy of anti-EGFR inhibitors with their ability to inhibit STAT3 activity in A431 epidermoid carcinoma cells and in a series of wt K-RAS expressing human colon cancer cell lines. Furthermore, the ability of cetuximab to inhibit growth also correlated with its ability to inhibit STAT3 activity in tumor xenograft animal studies. In addition, stable knockdown of the STAT3 phosphatase, protein tyrosine phosphatase receptor delta (PTPRD) resulted in enhanced STAT3 activity and subsequent resistance to cetuximab in DIFI colon carcinoma cells. This resistance could be reversed by STAT3 inhibition. Finally, HN5 cells with acquired resistance to the EGFR tyrosine kinase inhibitor, AG1478 displayed greater STAT3 activity than the HN5 control cell line. These AG1478-refractory HN5 cells were re-sensitized to AG1478, cetuximab and erlotinib when co-treated with a STAT3 inhibitor. Taken together, our current data indicates a key role of STAT3 activity in promoting resistance to anti-EGFR therapy and suggests that anti-EGFR therapy in combination with inhibitors that block STAT3 may provide therapeutic benefit for patients with mCRC and other EGFR driven tumor types.
Internal ID Number: 24556630
URI: http://ahro.austin.org.au/austinjspui/handle/1/12088
DOI: 10.4161/cbt.28179
URL: http://www.ncbi.nlm.nih.gov/pubmed/24556630
Type: Journal Article
Subjects: EGFR
STAT3
cetuximab
colon cancer
Animals
Antibodies, Monoclonal, Humanized.pharmacology.therapeutic use
Antineoplastic Agents.pharmacology
Cell Line, Tumor
Colonic Neoplasms.drug therapy.pathology
Drug Resistance, Neoplasm.drug effects
Heterografts
Humans
Mice, Inbred BALB C
Quinazolines.pharmacology
Receptor, Epidermal Growth Factor.antagonists & inhibitors.metabolism
Receptor-Like Protein Tyrosine Phosphatases, Class 2.genetics
STAT3 Transcription Factor.antagonists & inhibitors.metabolism
Tyrphostins.pharmacology
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.